REMAP-CAP
Summary
This is an international randomised controlled trial, looking at the effect of a number of different drugs has on those with significant community-acquired pneumonia. It is targeted towards those who are in ICU. Those who are on a Covid-19 ward should be directed towards the Recovery Trial.
Priority
This is a study which is considered a national priority.
Treatment
Participants will be randomised into one of a number of treatment arms, depending on local drug availability, including
- steroids,
- macrolides,
- antivirals and
- immunomodulators
Who can participate?
Patients will be eligible if they are
- Adults admitted to ICU
- Symptoms
- Confirmation of SARS-CoV-2 infection by PCR
- No medical history that might, in the opinion of the attending clinician, put the patient at significant risk if he/she were to participate in the trial. The R&I Team have expertise to be able to guide on this.
External Trial Website
